A Randomized, Double-Blind, Controlled Phase I Trial to Evaluate the Safety, Tolerability, and Immunogenicity of DCB07010 Adjuvant Given Intranasally at Ascending Dose Levels and Co-Administered with Trivalent Inactivated Influenza Virus Antigen (II)

2013-11-012024-05-13https://scholars.lib.ntu.edu.tw/handle/123456789/647878A Randomized, Double-Blind, Controlled Phase I Trial to Evaluate the Safety, Tolerability, and Immunogenicity of DCB07010 Adjuvant Given Intranasally at Ascending Dose Levels and Co-Administered with Trivalent Inactivated Influenza Virus Antigen (II)